/

Reata Pharmaceuticals, Inc.

RETA US

RETA USReata Pharmaceuticals, Inc.

United States Composite

172.36

USD

+0.02

(+0.01%)

-2.31EPS Dil.

-72.69P/E

6.52BMarket Cap

Next Earnings

November 6

Held by Insiders

4.10%

Held by Institutions

88.47%

Short % of Float

10.66%

YTD Yield

68.91%

3Y Yield

72.10%

5Y Yield

114.35%

Capital Structure

FRC

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

ST Debt

LT Borrowings

- -

LT Finance Leases

117

118

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

1,393

3,412

3,859

Working Capital

FRC

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

Total Current Assets

398

333

402

Cash, Cash Equivalents & STI

388

321

330

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

125

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

-32.75%

-81.82%

Net Income, GAAP

-NaN%

-67.42%

-5.05%

Free Cash Flow

-NaN%

-38.14%

12.24%

Total Cash Common Dividend

- -

Total Equity

-NaN%

274.90%

-135.48%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

- -

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-1.86

-2.00

-1.97

-2.35

-8.19

2022

-2.03

-2.02

-2.16

-2.33

-8.54

2023

-3.14

5.12

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. J. Warren Huff
Full Time Employees: 321
Sector: Healthcare
Industry: Biotechnology
Address: 5320 Legacy Drive Plano TX United States 75024
IPO Date: May 26, 2016
CIK: 0001358762
Website: www.reatapharma.com
Business: Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Company Description

CEO: Mr. J. Warren Huff
Full Time Employees: 321
Sector: Healthcare
Industry: Biotechnology
Address: 5320 Legacy Drive Plano TX United States 75024
IPO Date: May 26, 2016
CIK: 0001358762
Website: www.reatapharma.com
Business: Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.